Clearside Biomedical has announced that its licensing partner, REGENXBIO, has dosed the first patient in its Phase 2 clinical trial to evaluate the suprachoroidal delivery of RGX-314, an adeno-associated virus (AAV) gene therapy, using Clearside’s SCS Microinjector® for the treatment of wet age-related macular degeneration (wet AMD).
“We are pleased to see the progress made by REGENXBIO using our proprietary SCS Microinjector® for the suprachoroidal delivery of its innovative gene therapy into the back of the eye,” said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer. “Our targeted drug delivery approach has broad applicability utilizing proven compounds, novel small molecules, and gene therapy to deliver treatment in an office-based, non-surgical procedure. We believe this route of administration represents an important potential advancement in patient care.”
Clearside’s patented, proprietary suprachoroidal space (SCS®) injection treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. Clearside’s proprietary SCS Microinjector® can be used to inject a wide variety of drug candidates that are specifically formulated to be delivered via suprachoroidal injection. The SCS Microinjector provides targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. The SCS Microinjector is composed of a syringe and two 30-gauge hollow microneedles of varying lengths, each less than 1.2 millimeters, within a custom-designed hub that optimizes insertion and suprachoroidal administration of drugs.